help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biollaz, J.
Right arrow Articles by Gavras, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biollaz, J.
Right arrow Articles by Gavras, H.

Journal of Clinical Endocrinology & Metabolism, Vol 54, 1187-1193, Copyright © 1982 by Endocrine Society

ARTICLES

Escape from mineralocorticoid excess: the role of angiotensin II

J Biollaz, J Durr, HR Brunner, M Porchet and H Gavras

Escape from the sodium-retaining action of mineralocorticoids coincides with the suppression of plasma renin and angiotensin II levels. The purpose of this study was to evaluate whether blockade of the renin system accelerates this escape. Eight male normotensive volunteers, aged 24--33 yr, were maintained during two subsequent periods of 12 days each, separated by 3--4 weeks, on a constant intake of sodium and potassium of 140 mmol/day. During both periods, fludrocortisone acetate (0.2 mg) was administered orally three times a day on days 4--12. In addition, on days 3--12, either a converting enzyme inhibitor (MK 421;20 mg orally, twice daily) or a placebo was added in double blind fashion and randomized sequence. During both periods, blood pressures were similar; they tended to increase slightly toward day 12. The weight increase did not differ between the two periods. With MK 421, angiotension II levels were significantly lower than with placebo on days 3--6 (P less than 0.001). On the same days, PRA was increased due to converting enzyme blockade. Despite the significantly different angiotensin II levels on days 3--6, daily urinary sodium excretion on all individual days as well as cumulative sodium balance were the same during both periods. Therefore, we could find no evidence in man that suppression of circulating angiotensin II levels is causally related to escape from mineralocorticoid excess.


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
L. M. Prisant, H. Krum, B. Roniker, S. L. Krause, K. Fakouhi, and W. He
Can Renin Status Predict the Antihypertensive Efficacy of Eplerenone Add-On Therapy?
J. Clin. Pharmacol., November 1, 2003; 43(11): 1203 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. P. Granger, S. Kassab, J. Novak, J. F. Reckelhoff, B. Tucker, and M. T. Miller
Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 1999; 276(1): R197 - R202.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society